Tectonic Therapeutic Inc., a clinical stage biotechnology company, has announced its financial results for the first quarter ending March 31, 2025. The company reported research and development expenses of $13.0 million, an increase from $10.8 million in the same period the previous year. This rise was primarily attributed to higher costs related to the discovery and development of Tectonic's product candidate TX2100 for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT). General and administrative expenses also saw an increase, reaching $5.3 million from $2.2 million, driven by higher costs for audit, legal, and professional services, as well as increased non-cash stock-based compensation. Tectonic Therapeutic continues to advance its TX45 program, with interim analysis from the Phase 1b Part A trial showing meaningful improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). Full results from this trial are set to be presented on May 17, 2025, at the ESC Heart Failure Congress in Belgrade, Serbia. The company has also initiated Part B of the TX45 Phase 1b trial in March, with topline results expected in the second half of 2025. Additionally, the TX45 APEX Phase 2 trial is ongoing, with topline results anticipated in 2026. As of March 31, 2025, Tectonic reported cash and cash equivalents totaling $306.2 million, bolstered by private placement net proceeds raised in February 2025. This financial position is expected to provide the company with a cash runway into the fourth quarter of 2028.